19 December 2025
Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease Therapy
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| James Lu Lead | Sidley | Partner | Emerging Companies and Venture Capital | Not stated |
| Adam Welland Lead | Sidley | Counsel | Technology and Life Sciences Transactions | Not stated |
| Torrey Cope | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Rollin Ransom | Sidley | Not stated | Commercial Litigation and Disputes | Not stated |
| Eric Schwartz | Sidley | Not stated | Commercial Litigation and Disputes | Not stated |
| Jean Qiu | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.37bn (approximately US$1.37 billion)
- What the figure measures
- Total transaction value
- Client
- Changchun GeneScience (GenSci) PharmaceuticalsSell-side
- Counterparties
- Yarrow Bioscience (Buy-side)
RTW Investors (Investor)